OKYO Pharma Limited (OKYO)
Nasdaq · Healthcare · Biotechnology
$1.470.00%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $77.1M
- 52-week range
- $1.26 – $3.20
- 52-week change
- −27.94%
- EPS (trailing)
- −$0.24
About OKYO Pharma Limited
OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Headquarters: London, United Kingdom · 5 employees · okyopharma.com